Viral Genomix Inc. was founded in April of 2000 ; In 2006, it changed its name to , VGX Pharmaceuticals Inc. . This is the "root" of the corporation that eventually becomes known as Inovio Pharmaceuticals, Incorporated.
[...]
In 2005, Genetronics Biomedical Corporation purchased a Norwegian company called Inovio AS ( Source: [HW009F][GDrive] ); shortly afterwards, this combined corporation was renamed to Inovio Biomedical Corporation .
In Feb 2007, VGX Pharmaceuticals Inc. purchases/merges with ADViSYS Inc. .
In June 2009, VGX Pharmaceuticals Inc. purchased Inovio Biomedical Corporation , and the combined company was retained the name Inovio Biomedical Corporation . In May 2010, Inovio Biomedical Corporation was renamed to Inovio Pharmaceuticals, Incorporated.
[...]
...
Inovio AS ...
VGX Pharmaceuticals Inc. ( ... )
[...]
Inovio started out as Biotechnologies & Experimental Research, Inc. in 1983. The company's focus was on creating products for the research marketplace. In 1994, the company changed its name to Genetronics and went public by exchanging shares with Consolidated United Safety Technologies, which was listed on the Vancouver Stock Exchange. Consolidated United Safety Technologies got its start back in 1979, and was initially named Concord Energy Corp.
In 1997, Genetronics switched to the Toronto Stock Exchange. A year later, the company listed on the American Stock Exchange. It also remained on the Toronto Stock Exchange until 2003.
The company's focus during much of its early period as a U.S. stock was on electroporation, a technology for introducing DNA and drugs into cells through a brief electrical pulse that causes tiny pores to open in the cell membrane. Genetronics developed drug delivery systems using electroporation and sold electroporation equipment to the research laboratory market.
In early 2005, Genetronics acquired Norwegian gene delivery technology company Inovio AS. Shortly thereafter, Genetronics changed its name to Inovio Biomedical Corporation. Electroporation drug delivery remained a core focus of the company.
This period in the stock history wasn't the best for shareholders as Inovio faced several problems.
In June 2007, Inovio announced that it would halt enrollment in two late-stage clinical studies for squamous cell head and neck cancer using its Selective Electrochemical Tumor Ablation (SECTA) investigational therapy. The trials' independent data monitoring committee expressed concerns about both efficacy and safety. Inovio stock cratered on the news.
The company also had to restate its 2006 annual and 2007 quarterly financial statements. Inovio's audit committee found issues related to the classification of registered warrants issued by the company. In addition, like nearly every other stock, Inovio stock was hammered by the financial crisis that emerged in 2008.
Viral Genomix began operations in 2000 with a focus on developing DNA-based immunotherapies to treat infectious diseases and cancers. The company was renamed VGX Pharmaceuticals in 2006. On June 1, 2009, Inovio Biomedical merged with VGX Pharmaceuticals, picking up cervical dysplasia vaccine VGX-3100 in the process.
Inovio's pipeline at that time also included several early-stage and pre-clinical DNA vaccines targeting infectious diseases such as avian influenza, hepatitis C, and HIV. The company still, however, used its electroporation technology for delivery of the DNA vaccines into cells.
Initial excitement among investors about the VGX merger faded quickly, and Inovio stock continued its downward trend.
Inovio kept its focus on targeting viruses using DNA vaccines delivered through electroporation. However, the company also continued to study DNA vaccines for treating cancers not caused by viruses, including chronic and acute myeloid leukemia and prostate cancer.
The stock enjoyed two nice runs over the last four years. In 2013, the company reported encouraging pre-clinical results for its influenza DNA vaccine followed by more good news from a couple of early-stage studies for its HIV vaccine. There was even speculation that Inovio could be bought out.
More recently, Inovio enjoyed a lot of positive publicity and investor excitement related to its Zika virus vaccine program. In June 2015, the company became the first to win approval from the U.S. Food and Drug Administration (FDA) to initiate clinical studies in humans for an experimental Zika vaccine.
However, Inovio also encountered an obstacle for its experimental VGX-3100 cervical dysplasia vaccine. In October 2016, the FDA placed a clinical hold on the company's planned late-stage study of the vaccine, requesting additional information about the delivery device.
What does the future hold for Inovio? The company still hopes to win approval for VGX-3100 and advance cervical cancer vaccine INO-3112, which combines VGX-3100 with DNA-based immune activator encoded for IL-12. Inovio would like to be first to market with a Zika vaccine. The company has come a long way from its Genetronics days -- but there's still a long way to go before Inovio can enjoy the success that its shareholders have long hoped for.
1985-08-29-arizona-daily-star-pg-6b
1985-08-29-arizona-daily-star-pg-6b-clip-cells
1988-12-03-the-spokesman-review-spokane-wa-pg-b6.jpg
1988-12-03-the-spokesman-review-spokane-wa-pg-b6-clip-transtector.jpg
1D
https://www.newspapers.com/image/325059868
3D
https://www.newspapers.com/image/325059970/?terms=%22Genetronics%22&match=1
1997 (July 01)
https://www.newspapers.com/image/579863207/?terms=%22Genetronics%22&match=1
D1 https://www.newspapers.com/image/577369653
D2 https://www.newspapers.com/image/577369659/?terms=%22Genetronics%22&match=1
https://www.wsj.com/articles/SB93698594663702572?mod=Searchresults_pos4&page=1
1999-09-10-wsj-banks-lead-stock-advance.pdf
"Genetronics Biomedical Ltd. ended up C$0.60 to C$5.60, adding to Thursday's 0.20 rise, after president and chief executive Lois Crandall and chairman and chief scientific officer Gunter Hofmann both retired. Chief financial officer Martin Nash was named president and chief executive."
https://www.wsj.com/articles/SB975376486488912650?mod=Searchresults_pos3&page=1
2000-11-28-wsj-whos-news-briefs.pdf
"GENETRONICS BIOMEDICAL Ltd. (San Diego) -- Mervyn J. McCulloch, 57, was named chief financial officer of this developer of technology and hardware used in the delivery of drugs or genes. The new chief financial officer succeeds Martin Nash, 53, who remains president and CEO. Mr. McCulloch most recently was chief financial officer of Resources Connection Inc., a professional-services firm."
OVERVIEW
https://sec.report/Document/0001095811-01-502854/
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) June 15, 2001
Genetronics Biomedical Corporation
"On June 15, 2001, Genetronics Biomedical Ltd. completed a change in its jurisdiction of incorporation from British Columbia, Canada to Delaware. This change was accomplished through a domestication of Genetronics Biomedical Ltd. into Genetronics Biomedical Corporation, a Delaware corporation, pursuant to the corporate laws of both British Columbia and Delaware. The domestication will not result in any change in Genetronics’ business or assets, liabilities, net worth and management, nor will the continuation impair any creditors’ rights. The domestication is not, in itself, a corporate reorganization, amalgamation or merger. Exhibit 99 is a press release issued to announce the completion of this domestication."
[Genetronics News Release letterhead]
Contact: Mervyn J. McCulloch (CFO), Genetronics Biomedical Corporation, [...]
GENETRONICS BIOMEDICAL LIMITED COMPLETES CORPORATE CONTINUATION TO DELAWARE
San Diego, CA., June 18, 2001 -- Genetronics Biomedical Ltd. (AMEX and TSE: GEB)
today announced it completed a change in its jurisdiction of incorporation from
Vancouver, British Columbia, Canada on Friday, June 15, 2001. The change was
accomplished through a continuation of Genetronics Biomedical Ltd. into
Genetronics Biomedical Corporation, a Delaware corporation.
Grant Denison, Jr., Genetronics President and CEO commented, "We are pleased
with the overwhelming support that this proposal has received from our
stockholders. This allows Genetronics to become a Delaware corporation with all
the entitlements afforded by being incorporated in the United States."
The continuation into Delaware was approved by an overwhelming majority of
Genetronics' stockholders at an extraordinary general meeting held on May 22,
2001. Ninety-nine percent of votes cast were in favor of the proposal to change
the Company's jurisdiction of incorporation. The continuation was also approved
by the Genetronics Board of Directors at a meeting held on June 8, 2001.
The continuation will not result in any change in Genetronics' business or
assets, liabilities, net worth or management, nor will the continuation impair
any creditors' rights. The continuation is not, in itself, a corporate
reorganization, amalgamation or merger. The continuation into Delaware also
allows Genetronics to operate under the flexible, highly developed and
predictable Delaware corporate legal system.
The Company will continue to trade on the American and Toronto Stock Exchanges
under the symbol "GEB." As part of the continuation, each share of Genetronics
Biomedical Ltd. was automatically converted into one share of Genetronics
Biomedical Corporation. It is not necessary for stockholders to exchange their
existing stock certificates for stock certificates of the Delaware corporation.
All new shares will be issued from the Delaware corporation. The Company will
also change its fiscal year end from March 31 to December 31.
Genetronics will continue to operate through its wholly owned San Diego
subsidiary, Genetronics, Inc. and specialize in targeted intracellular delivery
of large molecule therapeutics. Concentrating on oncology and gene therapy,
Genetronics is developing its proprietary platform technology, Electroporation
Therapy, with the aim of enhancing patients' quality of life and providing safe,
effective and comparatively low-cost treatment. In the field of oncology,
development programs focus on diseases with high unmet need, including cancers
of the head and neck, liver, pancreas and skin. Genetronics BTX Instrument
Division, a leader in molecular delivery, featuring electroporation and
electrofusion technology for the research laboratory, markets an extensive line
of products for in vitro, ex vivo, and animal in vivo applications worldwide.
More information can be found at www.genetronics.com.
This press release contains certain forward-looking statements relating
to the Company's plans to develop its electroporation drug delivery system. The
availability of resources to support operations and plans for obtaining
additional financing cannot be assured. Actual events or results may differ from
the Company's expectations as a result of a number of factors, including the
uncertainties inherent in clinical trials and product development programs,
evaluation of potential opportunities, the level of corporate expenditures,
capital market conditions, and others set forth in the Genetronics Annual
Report, on Form 10-K and other regulatory filings. There can be no assurance
that any product in the Genetronics product pipeline will be successfully
developed or manufactured, or that final results of human pilot studies or
clinical studies will be supportive of regulatory approvals required to market
products. The American and Toronto Stock Exchanges have not reviewed and do not
accept responsibility for the adequacy or accuracy of this release
2002-02-25-wsj-clear-harbor-level-3.pdf
"Amex-traded Genetronics Biomedical, a San Diego drug-delivery company, fell 18 cents, or 29%, to 45 cents. The company's auditor said in an SEC filing that it has doubts about the company's ability to continue as a going concern, citing a lack of sufficient working capital to fund operations for all of 2002."
2003 (Feb 03)
https://www.outsourcing-pharma.com/Article/2003/02/03/Genetronics-approves-BTX-sale
2003-02-03-outsourcing-pharma-com-article-genetronics-approves-btx-sale-img-1.jpg
http://test.pharmabiz.com/news/genetronics-gets-two-new-patents-for-electroporation-therapy-15994
San Diego | Saturday, June 14, 2003, 08:00 Hrs [IST]
Genetronics Biomedical Corporation has been granted two new U.S. patents covering different aspects of its electroporation technology for medical applications. In the first patent, U.S. Patent Number 6,569,149, entitled, "Method of Treatment Using Electroporation Mediated Delivery of Drugs and Genes," the company has been allowed claims to methods for applying electric fields to patient tissue afflicted with a cell proliferation disorder, using the company's proprietary and patented field generating methodologies, particularly the use of multiple opposed pairs of electrodes.
In the second patent, U.S. Patent Number 6,567,694, entitled, "Needle Electrodes for Mediated Delivery of Drugs and Genes," claims were granted for an electrode apparatus for the application of electric fields wherein electrodes are positioned within a hollow needle. The Company believes this electrode configuration may be useful in the delivery of gene therapeutics and DNA vaccines.
Avtar Dhillon, Genetronics' President and CEO, said, "The claims of the two new patents cover differing electrode formats for performing electroporation in cancerous tissues and in micro-environments, respectively. The new patents are an important part of Genetronics' ongoing strategy to maintain its commercial position in developing medical applications of electroporation."
Mentioned - Inovio AS / Genetronics Biomedical Corporation / Dr. Avtar Singh Dhillon (born 1961) /
SAN DIEGO and OSLO, Norway, Jan. 26 /PRNewswire-FirstCall/ -- [ Genetronics Biomedical Corporation]. , a late stage developer of oncology and other therapies using electroporation to deliver drugs and nucleic acids, announced today the acquisition of Oslo-based [Inovio AS ], a leader in patented gene delivery technology for the most efficient, nonviral method for gene transfer to skeletal muscles. Inovio's use of electroporation for gene therapy and DNA vaccines is a complement to Genetronics' existing electroporation therapy program. The acquisition expands Genetronics' intellectual property in electroporation, expands the number of agreements with major pharmaceutical companies, and provides for the near-term initiation of a Phase I/II DNA vaccine clinical trial.
The deal includes cash in Inovio's treasury of approximately $775,000 and approximately $2.0M in current and anticipated appropriations for biodefense research from the US Army and other committed grants. The share purchase agreement consists of $3M in cash, $7M in Genetronics stock, and potential additional share payments given the achievement of certain revenue milestones. In addition, Iacob Mathiesen, Ph.D., Inovio's CEO, will serve as Executive Director, Gene Delivery of Genetronics.
"This is a perfect strategic fit as we increase our licensing activities in the area of DNA therapies involving intramuscular electroporation for application to vaccines and immunotherapy," said [Dr. Avtar Singh Dhillon (born 1961)], Genetronics' President and CEO. "Together with Dr. Mathiesen and his team, we will promote and advance gene-based collaborations with existing and new partners. We anticipate that license revenue from our DNA delivery technology will be increasingly important in creating additional value for our shareholders."
"I am delighted to bring our technology and products to [ Genetronics Biomedical Corporation], the market leader in electroporation-based therapies," noted Iacob Mathiesen, Ph.D., [the CEO of Inovio AS]. "Genetronics is in an enviable position to enable the advancement of DNA vaccinations and gene therapy, and I am certain that the company will play a prominent role in this promising and rapidly growing area."
https://www.sec.gov/Archives/edgar/data/1055726/000129993304000730/exhibit2.htm
2004-09-13-genetronics-press-release-archived-on-sec-site-1055726-000129993304000730.pdf
SAN DIEGO, CA., September 13, 2004 — Genetronics Biomedical Corporation (AMEX: GEB), a late stage developer of cancer and other therapies using electroporation-enabled delivery of drugs, DNA vaccines, and genes, announced today that the company’s board of directors has approved a 1-for-4 reverse stock split of its shares. The common stock will begin trading on a reverse split basis on the American Stock Exchange as of the opening of trading today, Monday, September 13, 2004. There is no symbol change.
Total shares voted, 56,578,878, was equal to 66.2% of total voteable shares (voteable shares include common shares plus common-share-equivalent voting rights attached to outstanding preferred shares). Shares voted in favor of the reverse split amounted to 49,201,399, or 87% of votes cast.
“Our company’s shareholders clearly indicated their strong support for the proposed reverse split, and the board of directors and management moved decisively to implement this resolution,” said Avtar Dhillon, MD, President & CEO. “We believe we are in a solid position to continue to execute on the fundamentals that will allow us to advance our electroporation therapy towards commercialization, which is expected to begin in 2005 in Europe.”
About Genetronics Biomedical Corporation
Genetronics Biomedical Corporation is a late stage biomedical company focused on building an oncology franchise based on its proprietary electroporation therapy. The therapy targets a significant unmet clinical need: the selective killing of cancer cells and local ablation of solid tumors while preserving healthy tissue. The company is moving its lead product, the MedPulser® Electroporation Therapy System, through pre-marketing studies for head and neck cancer in Europe, where it has CE Mark accreditation, and a U.S. Phase III pivotal study for recurrent head and neck cancer. Merck, Chiron, the US Navy, Vical and other partners are also employing Genetronics’ electroporation technology, which enhances local delivery of drugs and DNA, in their developments of novel DNA vaccines and gene therapies. Genetronics is a leader in electroporation, with over 240 patents worldwide that are issued, allowed or pending. More information can be obtained at www.genetronics.com.
***
This press release contains certain forward-looking statements relating to Genetronics’ plans to develop its electroporation drug and gene delivery technology and to maximize shareholder value. Actual events or results may differ from Genetronics’ expectations as a result of a number of factors, including the uncertainties inherent in clinical trials and product development programs, evaluation of potential opportunities, the level of corporate expenditures, the assessment of Genetronics’ technology by potential corporate partners, and capital market conditions, and others set forth in the Genetronics Annual Report, on Form 10-K for the 12-month period ending December 31, 2003, and the Form 10-Q for the 3-month period ending March 31, 2004, and other regulatory filings. There can be no assurance that any product in the Genetronics product pipeline will be successfully developed or manufactured, or that final results of human pilot studies or clinical studies will be supportive of regulatory approvals required to market Licensed Products. The American Stock Exchange has not reviewed and do not accept responsibility for the adequacy or accuracy of this release
https://www.newspapers.com/image/285964216/?terms=%22Inovio%20Biomedical%22&match=1